U.S. Markets closed

Theratechnologies Inc. (TH.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
7.49+0.10 (+1.35%)
At close: 4:34PM EDT

Theratechnologies Inc.

2015 Peel Street
5th Floor
Montreal, QC H3A 1T8

Full Time Employees26

Key Executives

Mr. Luc Tanguay M.Sc., C.F.A.Pres, CEO & Non-Independent DirectorN/AN/A59
Mr. Philippe Dubuc MBASr. VP & CFO284.6kN/A50
Mr. Jocelyn Lafond LL.B., L.L.M.VP of Legal Affairs & Corp. Sec.N/AN/A49
Mr. Christian Marsolais Ph.D.Sr. VP & Chief Medical OfficerN/AN/A54
Ms. Lyne Fortin MBA, B.Pharm.Sr. VP & Chief Commercial OfficerN/AN/A57
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Theratechnologies Inc., specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and an enhanced life among HIV patients. Its lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada. The company was founded in 1993 and is headquartered in Montreal, Canada.

Corporate Governance

Theratechnologies Inc.’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.